PE-22-28
Novel antidepressant peptide
Cognitivesubcutaneousmorning
Overview
Spadin analogue that modulates TREK-1 potassium channels. Shows antidepressant effects in research without typical SSRI side effects.
Dosing
- Typical Dosage
- 1-2 mg
- Frequency
- Daily
- Cycle Duration
- 2-4 weeks
- Administration
- subcutaneous
Available Vial Sizes
10mg
Research peptide for depression. Novel mechanism of action.
Comprehensive Information
AI-GeneratedGenerating comprehensive analysis...
This may take a moment
Mechanism of Action
Key Benefits
Optimal Timing
Potential Side Effects
Stacking Suggestions
Practical Tips
Could not load AI-generated information
Track Your PE-22-28 Protocol
Join UpgradeYourself to track your peptide protocols, log injections with our interactive body map, and receive AI-powered insights tailored to your health goals.
Free forever planNo credit card required100+ peptides tracked